Stock A003850 BORYUNG CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Boryung Corporation

Equities

A003850

KR7003850005

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 25/06/2024 BST 		5-day change 1st Jan Change
9,670 KRW -1.43% Intraday chart for Boryung Corporation -4.16% -18.67%
05-29 LambdaVision, Incorporated announced that it expects to receive funding from Aurelia Foundry, Aurelia Foundry Management Company, LLC, Boryung Corporation, E2MC CI
05-16 Boryung Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 697,868 952,407 965,199 596,925 783,143 642,154 -
Enterprise Value (EV) 2 791.9 1,039 1,071 710 852.2 748.7 680.8
P/E ratio 21.7 x 34.4 x 21.4 x 14.3 x 19.5 x 10.1 x 8.35 x
Yield 0.36% 0.52% 0.68% 1.1% 0.84% 1.03% 1.03%
Capitalization / Revenue 1.33 x 1.7 x 1.54 x 0.78 x 0.91 x 0.61 x 0.56 x
EV / Revenue 1.51 x 1.85 x 1.71 x 0.93 x 0.99 x 0.71 x 0.6 x
EV / EBITDA 14 x 15.6 x 14.7 x 7.62 x 9.03 x 5.45 x 4.24 x
EV / FCF -39.6 x 39.3 x 24.3 x 94.2 x 31.3 x 14 x 8.56 x
FCF Yield -2.53% 2.55% 4.11% 1.06% 3.2% 7.12% 11.7%
Price to Book 2.47 x 2.72 x 1.93 x 1.16 x 1.52 x 1.18 x 1.03 x
Nbr of stocks (in thousands) 55,481 59,994 66,110 65,886 65,866 66,407 -
Reference price 3 12,579 15,875 14,600 9,060 11,890 9,670 9,670
Announcement Date 30/01/20 05/02/21 17/03/22 06/02/23 29/01/24 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 524.3 561.9 627.3 760.5 859.6 1,050 1,137
EBITDA 1 56.49 66.78 72.74 93.16 94.38 137.3 160.6
EBIT 1 39.05 39.99 41.45 56.6 68.27 99.25 118
Operating Margin 7.45% 7.12% 6.61% 7.44% 7.94% 9.45% 10.37%
Earnings before Tax (EBT) 1 42.46 36.04 70.72 58.92 56.31 91.8 111.9
Net income 1 32.22 26.86 43.04 40.92 40.2 66.05 79.57
Net margin 6.15% 4.78% 6.86% 5.38% 4.68% 6.29% 7%
EPS 2 580.4 460.8 683.0 634.0 610.0 962.0 1,158
Free Cash Flow 3 -20,021 26,470 44,034 7,538 27,241 53,300 79,500
FCF margin -3,818.89% 4,711.1% 7,019.85% 991.2% 3,168.99% 5,074.26% 6,991.26%
FCF Conversion (EBITDA) - 39,637.57% 60,534.45% 8,091.42% 28,864.09% 38,810.68% 49,512.14%
FCF Conversion (Net income) - 98,562.38% 102,299.55% 18,422.29% 67,760.12% 80,696.44% 99,916.21%
Dividend per Share 2 45.46 83.33 100.0 100.0 99.97 100.0 100.0
Announcement Date 30/01/20 05/02/21 17/03/22 06/02/23 29/01/24 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 165.6 178.6 182.5 197.9 201.5 203.8 216.3 208.3 231.2 233.6 261 269.8 270.2
EBITDA - - - - - - - - - - - - -
EBIT 1 5.218 16.99 - 16.62 9.182 16 19.04 18.46 14.78 16.35 27.1 28.65 21.7
Operating Margin 3.15% 9.51% - 8.4% 4.56% 7.85% 8.8% 8.86% 6.39% 7% 10.39% 10.62% 8.03%
Earnings before Tax (EBT) 6.876 16.44 - - -8.517 15.83 - - - - - - -
Net income 1 5.677 11.18 15.1 - -6.339 11.35 - 11.94 5.738 23.4 18.95 20 11.8
Net margin 3.43% 6.26% 8.27% - -3.15% 5.57% - 5.73% 2.48% 10.02% 7.26% 7.41% 4.37%
EPS - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 17/03/22 16/05/22 16/08/22 14/11/22 06/02/23 27/04/23 27/07/23 25/10/23 29/01/24 30/04/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 94 86.8 106 113 69.1 107 38.6
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) 1.664 x 1.3 x 1.454 x 1.214 x 0.7319 x 0.7755 x 0.2404 x
Free Cash Flow 2 -20,021 26,470 44,034 7,538 27,241 53,300 79,500
ROE (net income / shareholders' equity) 12% 8% 10.6% 8.27% 7.79% 11.4% 12.4%
ROA (Net income/ Total Assets) 6.73% 4.3% 5.83% 4.87% 4.51% 6.8% 7.6%
Assets 1 478.8 624.2 738.3 840.4 892.4 971.3 1,047
Book Value Per Share 3 5,100 5,845 7,582 7,831 7,831 8,200 9,361
Cash Flow per Share 847.0 769.0 955.0 421.0 - - -
Capex 1 67 18.3 16.1 20.3 15 22.7 25.4
Capex / Sales 12.78% 3.25% 2.57% 2.67% 1.74% 2.16% 2.24%
Announcement Date 30/01/20 05/02/21 17/03/22 06/02/23 29/01/24 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Boryung Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9,670 KRW
Average target price
15,333 KRW
Spread / Average Target
+58.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
BORYUNG CORPORATION Stock Boryung Corporation
-18.67% 461M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.98% 43.67B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+25.90% 22.79B
SANDOZ GROUP AG Stock Sandoz Group AG
+19.25% 15.45B
CIPLA LIMITED Stock Cipla Limited
+18.35% 14.29B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+54.96% 12.83B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.98% 6.52B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.62% 5.59B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003850 Stock
  4. Financials Boryung Corporation